Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin versus tadalafil versus silodosin + tadalafil versus placebo for distal ureteric stone expulsion
PACTR202506759440037Phase 2Recruiting
- Sponsor
- Tanta University Hospitals
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of silodosin and tadalafil in ureterolithiasis (4 arms), sponsored by Tanta University Hospitals. Primary endpoint: Stone expulsion rate. Started Jul 2025; status: recruiting.
02
Drugs
silodosintadalafil
03
Conditions
ureterolithiasis
Beyond the preview
Go deeper on PACTR202506759440037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202506759440037.